Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension.
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension.
Am J Hypertens. 2019 Sep 21;:
Authors: Sanidas EA, Papadopoulos DP, Hatziagelaki E, Grassos C, Velliou M, Barbetseas J
Abstract
Sodium glucose cotransporter 2 (SGLT2) inhibitors represent a novel class of oral antihyperglycemic drugs that have been approved over the last decade for the management of type 2 diabetes mellitus. Except the glucose lowering effects, robust evidence also suggests that SGLT2 inhibitors confer benefits in cardiovascular system. The purpose of this review was to investigate the effects of SGLT2 inhibitors across the spectrum of arterial hypertension.
PMID: 31541572 [PubMed - as supplied by publisher]
Source: American Journal of Hypertension - Category: Cardiology Authors: Sanidas EA, Papadopoulos DP, Hatziagelaki E, Grassos C, Velliou M, Barbetseas J Tags: Am J Hypertens Source Type: research
More News: Academia | Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Hypertension | SGLT2 Inhibitors | Sodium